Arrowhead announces top line data from Phase III trials of plozasiran

Phase 3plozasiranPositive

AI Analysis

Summary

Arrowhead Pharmaceuticals announced top line results from Phase III SHASTA-3 and SHASTA-4 trials of plozasiran for severe hypertriglyceridemia. The company reported data from two pivotal trials but specific efficacy or safety outcomes were not detailed in this announcement.

Clinical Trial Data

Phase

Phase III

Importance:8/10

Sentiment:

0.60

Phase IIIData ReadoutplozasiranSHASTA-3SHASTA-4sHTG

Related Companies

$ARWR

Read the original article

Published by Clinical Trials Arena on July 23, 2026 9:54 AM

Read Original